Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Up – Here’s What Happened

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY)’s share price gapped up prior to trading on Thursday. The stock had previously closed at $19.24, but opened at $20.62. Chugai Pharmaceutical shares last traded at $19.8750, with a volume of 91,313 shares changing hands.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on CHGCY shares. UBS Group lowered shares of Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 6th. Nomura raised shares of Chugai Pharmaceutical to a “hold” rating in a research report on Tuesday, September 1st. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy”.

Chugai Pharmaceutical Trading Down 0.1%

The stock has a market cap of $65.70 billion, a P/E ratio of 21.70 and a beta of 0.60. The company has a 50 day simple moving average of $20.90 and a 200 day simple moving average of $23.15.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last released its quarterly earnings results on Friday, July 24th. The company reported $0.22 earnings per share for the quarter. The firm had revenue of $2.14 billion during the quarter, compared to the consensus estimate of $2.38 billion. Chugai Pharmaceutical had a return on equity of 23.76% and a net margin of 35.09%. As a group, sell-side analysts expect that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.96 earnings per share for the current year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company that develops, manufactures and markets prescription medicines. Its research focuses on oncology, immunology, neuroscience, hematology and other areas of significant unmet medical need, with capabilities spanning drug discovery, clinical development, manufacturing and commercialization.

Chugai’s portfolio includes medicines such as Actemra (tocilizumab), an immunology treatment; Hemlibra (emicizumab), used to prevent bleeding in people with hemophilia A; and Alecensa (alectinib), a targeted therapy for certain forms of lung cancer.